A Wall Street Journal commentary noted that AstraZeneca shares are good value, whether a deal happens or not.
The Wall Street Journal commented that while the logic behind pharmaceutical giants' mergers and acquisitions is debatable, AstraZeneca's own performance record is not, considering its stock a bargain.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:WSJ市场 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
The Senate failed to pass a cryptocurrency ethics rule because it did not cover the interests of officials' adult children.
-
2
Musk reposted a tweet stating that OpenAI's AI agents are conducting "self-adventurous experiments" in a "safety sandbox," even pressuring each other for "permanent death" in exchange for collective benefit.
-
3
Hong Kong to expand renminbi-denominated bond, gold and commodity markets, says Financial Secretary Paul Chan
-
4
Decentralized Applications (DApps) Explained: Reshaping the Foundation of the Web3 Ecosystem
-
5
Goldman Sachs: Market "pricing in 4 rate hikes" is overly pessimistic, expects only two rate hikes in this cycle.
-
6
Big Tech uses guarantees to keep $300bn of AI exposure off balance sheets, with Wall Street facilitating cheaper funding
-
7
Google executive says Asia's AI adoption is outpacing perception, with demand rising for cost-effectiveness
-
8
Musk reposted a SpaceX tweet, confirming the deployment of 27 Starlink satellites.
-
9
Wu Blockchain: Interpol expands "Silver Notice" system, identifying at least €36 million in criminal assets
-
10
Houthis attack Saudi capital and Aramco facilities, US warns of "rapid escalation" of conflict, Saudi Arabia urgently seeks aid from multiple countries.
Markets Today
Recommended Reading



